1. Spatiotemporal Changes of Fibronectin, Tenascin-C, Fibulin-1, and Fibulin-2 in the Skin During the Development of Chronic Contact Dermatitis 
Masashi Kusubata, Arisa Hirota, Tetsuya Ebihara, Kumiko Kuwaba, Youco Matsubara, Takako Sasaki, Moriaki Kusakabe, Teruyo Tsukada, Shinkichi Irie, Yoh-ichi Koyama 
Journal of Investigative Dermatology 
Volume 113, Issue 6, Pages (December 1999)
DOI: /j x
Copyright © 1999 The Society for Investigative Dermatology, Inc Terms and Conditions

2. Figure 1
Induction of chronic contact dermatitis. Temporal changes in ear thickness were measured throughout the experimental period (A), between day 6 and day 9 (B), and between days 66 and 69 (C). The right ear was treated with 0.2% DNFB (•), whereas the left ear was treated with vehicle (♦) every 3 d for 66 d. Thereafter, the thickness of the right ear (○) and the left ear (⋄) was measured without treatment. The DNFB-treated ear was significantly thicker than the vehicle-treated ear on day 6 and thereafter. *p < 0.05.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1999 The Society for Investigative Dermatology, Inc Terms and Conditions

3. Figure 2
Histology of the ear. The normal ear (A) and the DNFB-treated ear on day 9 (B) and day 30 (C) were stained with hematoxylin and eosin. Scale bar: 10 μm. Arrowheads indicate the position of the epidermal basement membrane. ★, scab; *, cartilage.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1999 The Society for Investigative Dermatology, Inc Terms and Conditions

4. Figure 3
Immunohistochemical staining of the ear. Fibronectin (FN; A–C), tenascin-C (TN; D–F), fibulin-2 (Fib2; G–I), and fibulin-1 (Fib1; J–L) of the normal ear (A, D, G, J), on day 6 (B, E, H, K), and day 30 (C, F, I, L) were stained by indirect immunofluorescence staining. Arrowheads indicate the epidermal basement membrane, and small arrows show the perichondrium. The large arrow in (D) indicates tenascin-C in the subcutaneous tissue of the inner side, and the large arrow in (G) shows the wall of a blood vessel. Scale bar: 10 μm.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1999 The Society for Investigative Dermatology, Inc Terms and Conditions

5. Figure 4
Western blot analysis of the ear. Fibronectin (FN; A, B), tenascin-C (TN; C, D), fibulin-2 (Fib2; E, F), and fibulin-1 (Fib1; G, H) of the vehicle-treated ear (A, C, E, G) and the DNFB-treated ear (B, D, F, H) were visualized using specific antibodies. Lanes 1–12 are days 0 (normal ear), 3, 6, 9, 12, 15, 18, 30, 42, 54, 66, and 97, respectively. Arrows in (A, B), (E, F), and (G, H) indicate 250 kDa fibronectin, 195 kDa fibulin-2, and 100 kDa fibulin-1, respectively. Large arrows and small arrows in (C, D) indicate a 230 kDa isoform and a 180 kDa isoform of tenascin-C, respectively.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1999 The Society for Investigative Dermatology, Inc Terms and Conditions

6. Figure 5
Gelatin zymography of the DNFB-treated ear. Lanes 1–9, days 0 (normal ear), 6, 9, 12, 18, 30, 42, 54, and 97, respectively; lane 10, culture supernatant of mouse osteosarcoma cells; lane 11, latent and active form of human MMP-2; lane 12, latent form of human MMP-9.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1999 The Society for Investigative Dermatology, Inc Terms and Conditions